Magazine Article | April 3, 2023

COVID Continues To Impact Outsourced Manufacturing And Supply Chain Security

Source: Life Science Leader

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

Each of the past three years, Industry Standard Research has included questions in its annual CDMO benchmarking research to better understand whether the pandemic has affected drug innovators’ outsourced manufacturing for small molecule drug substance, small molecule drug product, biologic drug substance, or biologic drug product. Among those who have been affected, we asked how their organization will mitigate the impact in the coming months and years. The data show that roughly half of respondents (53%) to the 2023 surveys confirmed the effects of the pandemic are still shaping their relationships and influencing their work with CDMOs. That’s a 3% reduction from the survey responses in 2022. Download the article to learn more.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader